Literature DB >> 8226322

Structure-antitumor activity relationship of semi-synthetic spicamycin analogues.

M Kamishohara1, H Kawai, A Odagawa, T Isoe, J Mochizuki, T Uchida, Y Hayakawa, H Seto, T Tsuruo, N Otake.   

Abstract

Spicamycin, a nucleoside antibiotic containing fatty acids with a variety of chain lengths (C12-C18), showed potent antitumor activity against human gastric cancer SC-9 and human breast cancer MX-1 in a xenograft model. We have made several semi-synthetic spicamycin analogues (SPMs) which differed in the chain length of the fatty acid moiety, and examined their structure-antitumor activity relationship. The cytotoxic activities of SPMs depended on the chain length of the fatty acid moiety, with dodecanoyl, tetradecanoyl, hexadecanoyl and icosanoyl analogues (SPM VIII, SPM X, SPM XII and SPM XVI) exhibiting the most potent cytotoxic activity against P388 murine leukemia cells. SPM VIII showed the most activity against SC-9 in the human tumor xenograft model with the highest therapeutic index among SPMs. The antitumor activity of SPM VIII was superior to that of mitomycin C.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8226322     DOI: 10.7164/antibiotics.46.1439

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

1.  d-Sedoheptulose-7-phosphate is a common precursor for the heptoses of septacidin and hygromycin B.

Authors:  Wei Tang; Zhengyan Guo; Zhenju Cao; Min Wang; Pengwei Li; Xiangxi Meng; Xuejin Zhao; Zhoujie Xie; Wenzhao Wang; Aihua Zhou; Chunbo Lou; Yihua Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-26       Impact factor: 11.205

2.  A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.

Authors:  S M Gadgeel; R R Boinpally; L K Heilbrun; A Wozniak; V Jain; B Redman; M Zalupski; R Wiegand; R Parchment; P M LoRusso
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

3.  The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.

Authors:  K Takara; Y Tanigawara; F Komada; K Nishiguchi; T Sakaeda; K Okumura
Journal:  Jpn J Cancer Res       Date:  2000-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.